Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium [177Lu] BL-ARC001 in advanced gastrointestinal and solid tumors
NCT07232407Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Dec 2027
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lutetium [177Lu] BL-ARC001 in gastrointestinal tumor and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 6 weeks, Maximum Tolerated Dose at 6 weeks and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
Lutetium [177Lu] BL-ARC001
03
Conditions
gastrointestinal tumorsolid tumor
Beyond the preview
Go deeper on NCT07232407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07232407.